ホーム>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>(+)-Aeroplysinin-1

(+)-Aeroplysinin-1 (Synonyms: NSC 170364)

カタログ番号GC18516

(+)-アエロプリシニン-1 ((+)-アエロプリシニン-1) は、海綿から分離された二次代謝産物であり、グラム陽性菌に対して強力な抗生物質効果を示し、HIV-1 に対して抗ウイルス活性を発揮します (IC50 = 14.6 μM)。

Products are for research use only. Not for human use. We do not sell to patients.

(+)-Aeroplysinin-1 化学構造

Cas No.: 28656-91-9

サイズ 価格 在庫数 個数
100μg
$163.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
(+)-Aeroplysinin-1 is a metabolite originally isolated from the marine sponge V. aerophoba with diverse biological activities. (+)-Aeroplysinin-1 (0.25-0.5 μM) induces cell death in MCF-7 and ZR-75-1 human breast cancer cells in a time- and concentration-dependent manner but has no effect on normal human fibroblasts at concentrations up to 5 μM. It also blocks EGF-induced endocytosis of the EGF receptor (EGFR) and EGF-dependent cell proliferation in MCF-7 cells. (+)-Aeroplysinin-1 inhibits bovine aortic endothelial (BAE) cell proliferation and cord formation in a Matrigel assay. It inhibits angiogenesis in a dose-dependent manner in a chick chorioallantoic membrane (CAM) assay when administered from 1.5 to 3 nmol per egg. (+)-Aeroplysinin-1 also has antibacterial activity against Gram-positive bacteria, including S. aureus, S. albus, and B. subtilis, but not Gram-negative bacteria and inhibits HIV-1 replication (IC50 = 14.6 μM) via inhibition of HIV-1 reverse transcriptase.

レビュー

Review for (+)-Aeroplysinin-1

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (+)-Aeroplysinin-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.